FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Rosenblum

Research Profile

Chemicals & Drugs

Disorders

Melanoma

Living Beings

Anatomy

Concepts & Ideas

Tissue Distribution

Co-author Network

Publications

TOP 3
Hong Zhou; Nhan L Tran; Michele B Weiss; Jeffrey A Winkles; Hideo Yagita; Kaushal Asrani; Sharron A N Brown; Emily Cheng; Suhendan Ekmekcioglu; Walter N Hittelman; John W Marks; Khalid A Mohamedali; Keeley K Phillips; Michael G Rosenblum
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
Khalid A Mohamedali; Gang Niu; Xiaoyuan Chen; Haokao Gao; Troy A Luster; Philip E Thorpe; Michael G Rosenblum
Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel.
Mi-Ae Lyu; John W Marks; Lawrence H Cheung; Min-Jeong Cho; Walter N Hittelman; Yuying Liu; Michael G Rosenblum
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Rosenblum (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hong Zhou; Nhan L Tran; Michele B Weiss; Jeffrey A Winkles; Hideo Yagita; Kaushal Asrani; Sharron A N Brown; Emily Cheng; Suhendan Ekmekcioglu; Walter N Hittelman; John W Marks; Khalid A Mohamedali; Keeley K Phillips; Michael G Rosenblum
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
The Journal of investigative dermatology 2013;133(4):1052-62.
2012: Khalid A Mohamedali; Gang Niu; Xiaoyuan Chen; Haokao Gao; Troy A Luster; Philip E Thorpe; Michael G Rosenblum
Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel.
Biochemical pharmacology 2012;84(11):1534-40.
2012: Mi-Ae Lyu; John W Marks; Lawrence H Cheung; Min-Jeong Cho; Walter N Hittelman; Yuying Liu; Michael G Rosenblum
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.
Cancer letters 2012;322(2):159-68.
2012: Mi-Ae Lyu; John W Marks; Lan V Pham; Bharat B Aggarwal; Kwang Seok Ahn; Lawrence H Cheung; Min-Jeong Cho; Richard J Ford; Walter N Hittelman; Bokyung Sung; Archito Tamayo; Michael G Rosenblum
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Biochemical pharmacology 2012;84(4):451-8.
2012: Fan Zhang; Lei Zhu; Ning Guo; Xinglu Huang; Seulki Lee; Guangming Lu; Khalid A Mohamedali; Gang Niu; Michael G Rosenblum; Magdalena Swierczewska; Andrew Y Wang; Hong Xu; Xiaoyuan Chen
Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles.
Biomaterials 2012;33(21):5414-22.
2011: Xiaoxia Wen; Rui Zhang; Qian Huang; Dong Liang; Wei Lu; Mi-Ae Lyu; Michael G Rosenblum; Chun Li
Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2011;13(4):721-9.
2011: Hong Zhou; Hideo Yagita; Lawrence H Cheung; Walter N Hittelman; John W Marks; Michael G Rosenblum; Jeffrey A Winkles
Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
Molecular cancer therapeutics 2011;10(7):1276-88.
2011: Khalid A Mohamedali; Zhi Gang Li; Michael W Starbuck; Xinhai Wan; Jun Yang; Sehoon Kim; Wendy Zhang; Michael G Rosenblum; Nora M Navone
Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2328-38.
2011: Khalid A Mohamedali; Latha Ramdas; Sophia Ran; Lawrence H Cheung; Candelaria Gomez-Manzano; Walter N Hittelman; Sehoon Kim; Philip E Thorpe; Johannes Waltenberger; Jing Xu; Wei Zhang; Michael G Rosenblum
Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.
BMC cancer 2011;11():358.
2010: Mi-Ae Lyu; Bokyung Sung; Lawrence H Cheung; John W Marks; Bharat B Aggarwal; Ricardo Aguiar; Michael G Rosenblum
The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Biochemical pharmacology 2010;80(9):1335-42.
2010: Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.
Neoplasia (New York, N.Y.) 2010;12(10):766-77.
2010: Mi-Ae Lyu; Deepak Rai; Kwang Seok Ahn; Bokyung Sung; Lawrence H Cheung; John W Marks; Bharat B Aggarwal; Ricardo Aguiar; Varsha Gandhi; Michael G Rosenblum
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Neoplasia (New York, N.Y.) 2010;12(5):366-75.
2009: Yu Cao; James D Marks; John W Marks; Lawrence H Cheung; Sehoon Kim; Michael G Rosenblum
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cancer research 2009;69(23):8987-95.
2009: Michael G Rosenblum; S Barth
Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions.
Current pharmaceutical design 2009;15(23):2676-92.
2008: Martin Rodriguez-Porcel; Weibo Cai; Olivier Gheysens; Jürgen K Willmann; kai chen; Hui Wang; Ian Y Chen; Lina He; Joseph C Wu; Zi-Bo Li; Khalid A Mohamedali; Sehoon Kim; Michael G Rosenblum; Xiaoyuan Chen; Sanjiv S Gambhir
Imaging of VEGF receptor in a rat myocardial infarction model using PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(4):667-73.
2008: Mi-Ae Lyu; Razelle Kurzrock; Michael G Rosenblum
The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Biochemical pharmacology 2008;75(4):836-46.
2008: Keith B Hartman; Lon J Wilson; Michael G Rosenblum
Detecting and treating cancer with nanotechnology.
Molecular diagnosis & therapy 2008;12(1):1-14.
2007: Sehoon Kim; Lawrence H Cheung; Weihe Zhang; Michael G Rosenblum
Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.
Applied microbiology and biotechnology 2007;77(1):99-106.
2007: Ramadevi Nimmanapalli; Mi-Ae Lyu; Min Du; Michael J Keating; Michael G Rosenblum; Varsha Gandhi
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
Blood 2007;109(6):2557-64.
2007: Andrew R Hsu; Weibo Cai; Anand Veeravagu; Khalid A Mohamedali; kai chen; Sehoon Kim; Hannes Vogel; Lewis C Hou; victor Tse; Michael G Rosenblum; Xiaoyuan Chen
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(3):445-54.
2007: Sehoon Kim; Khalid A Mohamedali; Lawrence H Cheung; Michael G Rosenblum
Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli.
Journal of biotechnology 2007;128(3):638-47.
2007: Mi-Ae Lyu; Lawrence H Cheung; Walter N Hittelman; John W Marks; Ricardo Aguiar; Michael G Rosenblum
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Molecular cancer therapeutics 2007;6(2):460-70.
2006: Weibo Cai; kai chen; Khalid A Mohamedali; Qizhen Cao; Sanjiv S Gambhir; Michael G Rosenblum; Xiaoyuan Chen
PET of vascular endothelial growth factor receptor expression.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(12):2048-56.
2006: Khalid A Mohamedali; Ann T Poblenz; Charles R Sikes; Nora M Navone; Philip E Thorpe; Bryant G Darnay; Michael G Rosenblum
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Cancer research 2006;66(22):10919-28.
2006: Jared M Ashcroft; Dmitri A Tsyboulski; Keith B Hartman; Tatiana Y Zakharian; John W Marks; R Bruce Weisman; Michael G Rosenblum; Lon J Wilson
Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody.
Chemical communications (Cambridge, England) 2006;(28):3004-6.
2006: Chu Ted; John W Marks; Laura A Lavery; Sarah Faulkner; Michael G Rosenblum; Andrew D Ellington; Matthew Levy
Aptamer:toxin conjugates that specifically target prostate tumor cells.
Cancer research 2006;66(12):5989-92.
2006: Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
Neoplasia (New York, N.Y.) 2006;8(5):384-93.
2006: Yuying Liu; Weihe Zhang; Ting Niu; Lawrence H Cheung; Anupama Munshi; Raymond E Meyn; Michael G Rosenblum
Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.
Neoplasia (New York, N.Y.) 2006;8(2):125-35.
2005: Hideo Akiyama; Khalid A Mohamedali; Raquel Lima E Silva; Shu Kachi; Jikui Shen; Christina Hatara; Naoyasu Umeda; Sean F Hackett; Sadia Aslam; Melissa Krause; Hong Lai; Michael G Rosenblum; Peter A Campochiaro
Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
Molecular pharmacology 2005;68(6):1543-50.
2005: Khalid A Mohamedali; Daniel Kedar; Paul Sweeney; Ashish Kamat; Darren W Davis; Beryl Y Eve; Samuel Huang; Philip E Thorpe; Colin P N Dinney; Michael G Rosenblum
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
Neoplasia (New York, N.Y.) 2005;7(10):912-20.
2005: Mi-Ae Lyu; Michael G Rosenblum
The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1.
Molecular cancer therapeutics 2005;4(8):1205-13.
2005: Sophia Ran; Khalid A Mohamedali; Troy A Luster; Philip E Thorpe; Michael G Rosenblum
The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.
Neoplasia (New York, N.Y.) 2005;7(5):486-96.
2005: Yuri A Mackeyev; John W Marks; Michael G Rosenblum; Lon J Wilson
Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubes.
The journal of physical chemistry. B 2005;109(12):5482-4.
2004: Kapil Mehta; Larry Ocanas; Fabio Malavasi; John W Marks; Michael G Rosenblum
Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells.
Molecular cancer therapeutics 2004;3(3):345-52.
2004: Yuying Liu; Lawrence H Cheung; John W Marks; Michael G Rosenblum
Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.
International journal of cancer. Journal international du cancer 2004;108(4):549-57.
2003: Yuying Liu; Lawrence H Cheung; Walter N Hittelman; Michael G Rosenblum
Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.
Molecular cancer therapeutics 2003;2(12):1341-50.
2003: Yuying Liu; Lawrence H Cheung; Philip E Thorpe; Michael G Rosenblum
Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells.
Molecular cancer therapeutics 2003;2(10):949-59.
2003: Michael G Rosenblum; Lawrence H Cheung; Yuying Liu; John W Marks
Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
Cancer research 2003;63(14):3995-4002.
2003: Hatice Duzkale; Lance C Pagliaro; Michael G Rosenblum; Ali Varan; Baoshun Liu; James M Reuben; William G Wierda; Martin Korbling; John McMannis; Armand B. Glassman; David A Scheinberg; Emil J Freireich
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(6):364-72.
2002: Omar Eton; Michael G Rosenblum; Sewa S Legha; Wehei Zhang; Mary Jo East; Agop Bedikian; Nicholas Papadopoulos; Antonio C Buzaid; Robert S Benjamin
Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Cancer 2002;95(1):127-34.
2002: Liesbeth M Veenendaal; Hangqing Jin; Sophia Ran; Lawrence Cheung; Nora M Navone; John W Marks; Johannes Waltenberger; Philip E Thorpe; Michael G Rosenblum
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(12):7866-71.
2000: Michael G Rosenblum; S A Horn; Lawrence H Cheung
A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor.
International journal of cancer. Journal international du cancer 2000;88(2):267-73.
1999: Michael G Rosenblum; Claire F Verschraegen; James L Murray; Andrzej P Kudelka; Jacalyn B Gano; Lawrence Cheung; John J Kavanagh
Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(5):953-61.
1999: Michael G Rosenblum; L K Shawver; John W Marks; J Brink; Lawrence Cheung; BC Langton-Webster
Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):865-74.
1999: Michael G Rosenblum; John W Marks; Lawrence H Cheung
Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Cancer chemotherapy and pharmacology 1999;44(4):343-8.
1998: Lance C Pagliaro; Baoshun Liu; R Munker; Michael Andreeff; Emil J Freireich; David A Scheinberg; Michael G Rosenblum
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1971-6.
1997: D J Macey; E J Grant; LeelapP Kasi; Michael G Rosenblum; Hua-Zhong Zhang; Ruth Katz; P T Rieger; D LeBherz; M South; J W Greiner; J Schlom; Donald A Podoloff; James L Murray
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1547-55.
1996: James L Murray; Eugenie S Kleinerman; Shu-Fang Jia; Michael G Rosenblum; Omar Eton; Antonio C Buzaid; Sewa S Legha; Merrick I Ross; L Thompson; K Mujoo; P T Rieger; M Saleh; M B Khazaeli; S Vadhan-Raj
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):206-17.
1996: Michael G Rosenblum; L Cheung; S K Kim; K Mujoo; Nicholas J Donato; James L Murray
Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Cancer immunology, immunotherapy : CII 1996;42(2):115-21.
1995: James L Murray; D J Macey; E J Grant; Michael G Rosenblum; L P Kasi; Hua-Zhong Zhang; Ruth Katz; P T Riger; D LeBherz; V Bhadkamkar
Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment.
Cancer research 1995;55(23 Suppl):5925s-5928s.
1995: Michael G Rosenblum; W A Kohr; Kenneth L Beattie; W G Beattie; W Marks; P D Toman; L Cheung
Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(6):547-55.
1995: K Mujoo; L Cheung; James L Murray; Michael G Rosenblum
Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.
Cancer immunology, immunotherapy : CII 1995;40(5):339-45.
1995: Michael G Rosenblum; L Cheung; K Mujoo; James L Murray
An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.
Cancer immunology, immunotherapy : CII 1995;40(5):322-8.
1994: Michael G Rosenblum; B Levin; M Roh; D Hohn; R McCabe; L Thompson; L Cheung; James L Murray
Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88.
Cancer immunology, immunotherapy : CII 1994;39(6):397-400.
1994: Peter Pritchard; R E Morton; Michael G Rosenblum; Gabriel Lopez-Berestein
Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.
Journal of pharmaceutical sciences 1994;83(7):1006-10.
1994: Roman Perez-Soler; Nicholas J Donato; Dong M Shin; Michael G Rosenblum; Hua-Zhong Zhang; C Tornos; H Brewer; J C Chan; Jin S Lee; Waun Ki Hong
Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):730-9.
1994: James L Murray; Michael G Rosenblum; Hua-Zhong Zhang; Donald A Podoloff; L P Kasi; Steven A Curley; J C Chan; M Roh; D C Hohn; H Brewer
Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients.
Cancer 1994;73(3 Suppl):850-7.
1994: James L Murray; D J Macey; L P Kasi; P Rieger; Joan E. Cunningham; V Bhadkamkar; Hua-Zhong Zhang; J Schlom; Michael G Rosenblum; Donald A Podoloff
Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
Cancer 1994;73(3 Suppl):1057-66.
1994: Peter Pritchard; Michael G Rosenblum; L Cheung; Gabriel Lopez-Berestein
Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.
Antimicrobial agents and chemotherapy 1994;38(2):223-7.
1994: K Nishikawa; J Rotbein; D Vijjeswarapu; Laurie B Owen-Schaub; Michael G Rosenblum; Nicholas J Donato
Positive and negative selection for tumor necrosis factor responsiveness reveals an inhibitory role for EGF receptor in TNF-induced antiproliferation.
Lymphokine and cytokine research 1994;13(1):37-45.
1993: Nicholas J Donato; Duen-Hwa Yan; Mien-Chie Hung; Michael G Rosenblum
Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1993;4(5):411-9.
1993: K Mujoo; Nicholas J Donato; Ruth Lapushin; Michael G Rosenblum; James L Murray
Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):166-74.
1992: Michael G Rosenblum; J E Zuckerman; John W Marks; J Rotbein; W R Allen
A gelonin-containing immunotoxin directed against human breast carcinoma.
Molecular biotherapy 1992;4(3):122-9.
1992: K Nishikawa; Michael G Rosenblum; Robert A Newman; Tej K Pandita; Walter N Hittelman; Nicholas J Donato
Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Cancer research 1992;52(17):4758-65.
1992: Nicholas J Donato; Michael G Rosenblum; PA Steck
Tumor necrosis factor regulates tyrosine phosphorylation on epidermal growth factor receptors in A431 carcinoma cells: evidence for a distinct mechanism.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(5):259-68.
1991: Michael G Rosenblum; John J Kavanagh; T W Burke; J T Wharton; Joan E. Cunningham; L J Shanken; E G Silva; L Thompson; L Cheung; L Lamki
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration.
Journal of the National Cancer Institute 1991;83(22):1629-36.
1991: Paul F Mansfield; M A Salmeron; Michael G Rosenblum; Kyogo Itoh
Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes.
International journal of cancer. Journal international du cancer 1991;49(3):356-61.
1991: L M Lamki; Aman U Buzdar; S E Singletary; Michael G Rosenblum; V Bhadkamkar; L Esparza; Donald A Podoloff; A Zukiwski; G N Hortobagyi; James L Murray
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1991;32(7):1326-32.
1991: Razelle Kurzrock; Moshe Talpaz; Zeev Estrov; Michael G Rosenblum; Jordan U Gutterman
Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1241-50.
1991: K Mujoo; Michael G Rosenblum; James L Murray
Augmented binding of radiolabeled monoclonal antibodies to melanoma cells using specific antibody combinations.
Cancer research 1991;51(11):2768-72.
1991: Nicholas J Donato; J Rotbein; Michael G Rosenblum
Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells.
Journal of cellular biochemistry 1991;46(1):69-77.
1991: Michael G Rosenblum
Biochemical effects of human alpha interferon in combination with alpha-difluoromethylornithine on human lymphoblastoid (DAUDI) cells in culture.
Lymphokine and cytokine research 1991;10(1-2):83-7.
1991: Michael G Rosenblum; James L Murray; L Cheung; R Rifkin; S Salmon; R Bartholomew
A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.
Molecular biotherapy 1991;3(1):6-13.
1991: James L Murray; K Mujoo; C Wilmanns; P Mansfield; D S Wilbur; Michael G Rosenblum
Variables influencing tumor uptake of anti-melanoma monoclonal antibodies radioiodinated using para-iodobenzoyl (PIB) conjugate.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1991;32(2):279-87.
1991: Michael G Rosenblum; L Cheung; James L Murray; R Bartholomew
Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance.
Cancer communications 1991;3(1):21-7.
1991: Paul F Mansfield; Michael G Rosenblum; James L Murray; Kyogo Itoh
Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
Cancer immunology, immunotherapy : CII 1991;33(4):247-54.
1991: K Mujoo; R A Reisfeld; L Cheung; Michael G Rosenblum
A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
Cancer immunology, immunotherapy : CII 1991;34(3):198-204.
1990: K Nishikawa; R A Newman; L Murray; Abdul R Khokhar; Michael G Rosenblum
Detection of cellular platinum using the monoclonal antibody 1C1.
Molecular biotherapy 1990;2(4):235-41.
1990: James L Murray; A A Zukiwski; K Mujoo; Michael G Rosenblum
Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.
Journal of biological response modifiers 1990;9(6):556-63.
1990: Michael G Rosenblum; W K Yung; P J Kelleher; F Ruzicka; PA Steck; Ernest C Borden
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
Journal of interferon research 1990;10(2):141-51.
1990: Michael G Rosenblum; James L Murray; S Stuckey; Robert A Newman; S Chaney; Abdul R Khokhar
Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody.
Cancer chemotherapy and pharmacology 1990;25(6):405-10.
1990: L M Lamki; Yehuda Z Patt; Michael G Rosenblum; L J Shanken; L B Thompson; S A Schweighardt; J M Frincke; James L Murray
Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody.
Radiology 1990;174(1):147-51.
1989: Nicholas J Donato; Gary E Gallick; PA Steck; Michael G Rosenblum
Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity.
The Journal of biological chemistry 1989;264(34):20474-81.
1989: James L Murray; Eugenie S Kleinerman; Joan E. Cunningham; J R Tatom; K Andrejcio; J Lepe-Zuniga; L M Lamki; Michael G Rosenblum; H Frost; Jordan U Gutterman
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1915-25.
1989: Nicholas J Donato; C Ince; Michael G Rosenblum; Gary E Gallick
Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
Journal of cellular biochemistry 1989;41(3):139-57.
1989: M Frontiera; James L Murray; L Lamki; J Thomas; W Satterlee; R Schmelter; Michael G Rosenblum; Muhammad B Khazaeli; M W Unger; William A Robinson
Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma.
Clinical nuclear medicine 1989;14(5):357-66.
1989: Michael G Rosenblum; Nicholas J Donato
Tumor necrosis factor alpha: a multifaceted peptide hormone.
Critical reviews in immunology 1989;9(1):21-44.
1988: James L Murray; L M Lamki; L J Shanken; M E Blake; Carl Plager; Robert S Benjamin; S Schweighardt; M W Unger; Michael G Rosenblum
Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans.
Cancer research 1988;48(15):4417-22.
1988: L M Lamki; James L Murray; Michael G Rosenblum; Yehuda Z Patt; R Joseph Babaian; M W Unger
Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of 111indium labelled (MoAb).
Nuclear medicine communications 1988;9(8):553-64.
1988: Yehuda Z Patt; L M Lamki; T P Haynie; M W Unger; Michael G Rosenblum; A Shirkhoda; James L Murray
Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(8):1220-30.
1988: Michael G Rosenblum; L Cheung; D Kessler
Differential activity of the 30-kD and the 100-kD forms of 2'-5'An synthetase induced by recombinant human interferon-alpha and interferon-gamma.
Journal of interferon research 1988;8(3):275-82.
1988: Michael G Rosenblum; L M Lamki; James L Murray; Dennis J Carlo; Jordan U Gutterman
Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients.
Journal of the National Cancer Institute 1988;80(3):160-5.
1988: James L Murray; S E Stuckey; J K Pillow; Michael G Rosenblum; Jordan U Gutterman
Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens.
Journal of biological response modifiers 1988;7(2):152-61.
1988: Michael G Rosenblum; Nicholas J Donato; Jordan U Gutterman
Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture.
Lymphokine research 1988;7(2):107-17.
1987: R Joseph Babaian; James L Murray; L M Lamki; T P Haynie; Evan M Hersh; Michael G Rosenblum; H J Glenn; M W Unger; Dennis J Carlo; A C von Eschenbach
Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276.
The Journal of urology 1987;137(3):439-43.
1987: James L Murray; Michael G Rosenblum; L Lamki; T P Haynie; H J Glenn; Carl Plager; M W Unger; Dennis J Carlo; Evan M Hersh
Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen.
NCI monographs : a publication of the National Cancer Institute 1987;(3):3-9.
1987: James L Murray; Michael G Rosenblum; L Lamki; H J Glenn; Z Krizan; Evan M Hersh; Carl Plager; Richard Bartholomew; M W Unger; Dennis J Carlo
Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1987;28(1):25-33.
1985: Z Krizan; James L Murray; Evan M Hersh; Michael G Rosenblum; H J Glenn; C R Gschwind; Dennis J Carlo
Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants.
Cancer research 1985;45(10):4904-9.
1985: Michael G Rosenblum; James L Murray; T P Haynie; H J Glenn; M F Jahns; Robert S Benjamin; J M Frincke; Dennis J Carlo; Evan M Hersh
Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.
Cancer research 1985;45(5):2382-6.
1985: James L Murray; Michael G Rosenblum; R E Sobol; Richard Bartholomew; Carl Plager; T P Haynie; M F Jahns; H J Glenn; L Lamki; Robert S Benjamin
Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5.
Cancer research 1985;45(5):2376-81.
1984: G Lopez-Berestein; L Kasi; Michael G Rosenblum; T Haynie; M Jahns; H Glenn; R Mehta; G M Mavligit; Evan M Hersh
Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer.
Cancer research 1984;44(1):375-8.